Neurocrine closes collaboration with Voyager; pays $136M upfront, buys $39M in stock

NEUROCRINE BIOSCIENCES INC

Collaboration Agreement with Voyager became effective Feb 21, 2023 after HSR waiting period expired.
Neurocrine paid Voyager ~$136M upfront and purchased 4,395,588 shares at $8.88/share for ~$39M.
Jude Onyia, Neurocrine's CSO, appointed to Voyager's board per Amended Investor Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.